Oncimmune Holdings plc has placed and converted debt into equity
Oncimmune Holdings plc has raised US$2.9 million (£2.3 million) by placing and converting debt into equity to advance its pioneering work in autoantibody profiling and biomarker discovery, along with an additional US$4.1 million (€4 million) from debt conversion.
Oncimmune Holdings plc develops and commercializes technologies for cancer diagnosis in the UK, North America, Europe and beyond. The company offers EarlyCDT-Lung, a blood test for the early detection of lung cancer. Additionally, Oncimmune develops SeroTag, a platform for discovering and validating biomarkers to help stratify patients across multiple cancer indications, infectious diseases and autoimmune conditions. The company also offers NavigAID disease-specific stratification panels. Founded in 2015, Oncimmune is based in Nottingham, UK.
Oaklins Cavendish, one of Oaklins’ member firms in the UK, advised Oncimmune Holdings plc on this transaction.
Falar com a equipa da transação
Transações relacionadas
Pharma-Skan & Skan-Medic have been acquired by Brygge Partners
Pharma-Skan, an independent contract manufacturing organization (CMO), and Skan-Medic, a manufacturer of over-the-counter (OTC) products, both operating as a joint entity, have been acquired by Brygge Partners.
Saber maisDarien S.p.A. has launched a voluntary public tender offer for NVP S.p.A.
Darien S.p.A. has initiated a voluntary public tender offer for NVP S.p.A.
Saber maisThe Canton of Solothurn had a valuation report prepared for its hospitals
The Canton of Solothurn is the owner of Solothurner Spitäler AG (soH), with its three hospitals in Solothurn, Olten and Dornach.
Saber mais